PRESS RELEASE

Lyon, September 3rd, 2025

ADOCIA

innovative medicine
for everyone, everywhere

ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings

6:00 p.m. CEST - Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announces oral presentations highlighting the latest preclinical results obtained on its innovative technological platform AdoShell® at EASD and ESB 2025 annual meetings. Adocia will also present at the next PODD 2025 its latest preclinical results on the BioChaperone® platform.

AdoShell®

The innovative AdoShell® technology platform is designed to implant human insulin-secreting cells from either deceased donors (islets of Langherans) or stem cells to provide a cure for Type 1 diabetes without the need for immunosuppression. Oral presentations at EASD et ESB will highlight the latest AdoShell® preclinical results[1]:

- Successful scale up from animal to human device for First-In-Human study
- In vitro and in vivo maturation after encapsulation of immature stem cell-derived islets in AdoShell®
- Sustained long-term in vivo function and efficacy of stem cell-derived islets encapsulated in AdoShell®

[1] *Press release of June 24, 2025 - ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to Stem Cell-Derived Islets.*

EASD (European Association for the Study of Diabetes) annual meeting, Vienna, Austria, 15-19 September 2025

- **Title**: ***ADO12, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression***
- **Presentation**: Tuesday, September 16th 2025 - 12:00 -13:00 pm CEST
- **Session**: It's beta cell replacement time (SO 019; 400)
- **Room**: Station 04
- **Authors**: **Ouardane Jouannot**, Anne-Lise Gaffuri, Madeleine Frelon, Gregory Blache, Julie Brun, Guillaume Lefebvre, Camille Gautier, Romain Besnard, Alexandre Martin, Claire Mégret, Nicolas Laurent, Martin Gaudier, Rosy Eloy, François Pattou, Olivier Soula
- **Links** : complementary information, included abstract, available on the EASD website

- **Title**: ***ADO12, a non-fibrotic encapsulation system enables stem cell-derived islets in vivo maturation for type 1 diabetes treatment***
- **Presentation**: Thursday, September 18th 2025 – 11:15 -11:30 am CEST
- **Session**: Guardians of the islet galaxy: protect and replace (OP 28; 165)
- **Room**: Sofia Hall
- **Authors**: **Ouardane Jouannot**, Alexandre Martin, Madeleine Frelon, Julie Brun, Camille Gautier, Clément Cocita, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Nicolas Laurent, Anne-Lise Gaffuri, Martin Gaudier, Rosy Eloy, Olivier Soula
- **Links** : complementary information, included abstract, available on the EASD website

ESB (European Society for Biomaterials) annual meeting, Torino, Italy, 7-11 September 2025

- **Title**: ***Development of a scalable reinforced hydrogel encapsulating human islets for type I diabetes treatment***
- **Presentation**: Tuesday, September 9th 2025 - 11:00 -12:30 am CEST
- **Session:** Advanced materials and technologies for health and disease (Session A6; 258)
- **Room**: Auditorium
- **Authors: Julie Brun**, Romain Besnard, Alexandre Geissler, Baptiste Plancq, Ouardane Jouannot, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Emmanuel Dauty, Olivier Soula
- **Links**: complementary information available on the ESB website

BioChaperone® GLP-1 – Amylin

BioChaperone® is a proprietary platform tailored to solve peptide formulation issues by means of non-covalent molecular complexation.

The oral presentation at the PODD (Partnership Opportunities in Drug Delivery) will highlight the latest preclinical results obtained with BioChaperone® CagriSema, a technology offering a stable combination of cagrilintide and semaglutide. Cagrilintide and semaglutide are long-acting peptide drugs having major compatibility issues. BioChaperone® CagriSema overcomes the incompatibility between the two APIs, in presence of antibacterial agents, making a co-formulation in multiple-dose pen injectors possible.

PODD (Partnership Opportunities in Drug Delivery) annual meeting, Boston, USA, 27-28 October 2025

- **Title**: ***Stable co-formulation of cagrilintide and semaglutide enabled by the BioChaperone® technology for multi-dose pen injectors***
- **Presentation**: Monday, October 27th 2025 - 2:45-3:00 pm EDT
- **Session**: Novel Materials & Excipient Innovation (5A)
- **Authors**: **Charles Fortier**, You-Ping Chan, Ulysse Naessens, Jenny Erales, Emmanuel Dauty, David Rigal, Audrey Maréchal, Joachim Garric, Grégory Blache, Claire Mégret, Martin Gaudier, Olivier Soula
- **Links**: complementary information available on the PODD website

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Contact

Adocia

Olivier Soula
CEO

contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com

Ulysse Communication

Adocia Press & Investor Relations
Bruno Arabian
Nicolas Entz

adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at www.adocia.com. Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.